By blocking the immune escape of tumor cells, immune checkpoint inhibitors (ICI) can activate immune response to attack tumor cells. ICI also causes a variety of immune related adverse events, among which cardiotoxicity is a rare but fatal one. With the increasing clinical use of ICI, cardiotoxicity attracts more attention. This article reviewed clinical manifestation, mechanism, diagnosis, treatment and prognosis of ICI induced cardiotoxicity.